Valuation: Summit Therapeutics Inc.

Market Cap 8.97B 12.04B 10.53B 9.71B 17.02B 1,148B 17.3B 116B 45.56B 565B 45.19B 44.21B 1,944B P/E 2026 *
-13.6x
P/E 2027 * -13.7x
Enterprise Value 8.71B 11.68B 10.22B 9.43B 16.52B 1,114B 16.8B 113B 44.23B 549B 43.87B 42.92B 1,887B EV / Sales 2026 *
3,557x
EV / Sales 2027 * 213x
Free-Float
16.86%
Yield 2026 *
-
Yield 2027 * -
1 day-1.49%
1 week-4.27%
Current month+4.67%
1 month+16.86%
3 months-22.47%
6 months-10.50%
Current year-12.81%
1 week 14.86
Extreme 14.86
16.05
1 month 12.92
Extreme 12.92
16.05
Current year 12.55
Extreme 12.5501
29.23
1 year 12.55
Extreme 12.5501
30.98
3 years 1.52
Extreme 1.52
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 54 25/07/2022
Chief Executive Officer 81 01/04/2020
Director of Finance/CFO 48 02/04/2024
Director TitleAgeSince
Chairman 81 01/02/2020
Director/Board Member 48 01/12/2019
Director/Board Member 54 11/11/2020
Date Insider Type Main position Quantity % Market Cap.
12/06Buy

Chief Executive Officer

3,810,000 0.4909%
12/06Other

Chief Executive Officer

0 0%
12/06Buy

Chief Executive Officer

3,810,000 0.4909%
Change 5-day change 1-year change 3-year change Capi.($)
-1.49%-4.27%-41.07%+609.30% 12.01B
-4.14%-7.44%+64.26%+119.36% 56.98B
+1.84%+1.65%+76.90%+95.68% 53.58B
-2.24%+3.65%+19.60%+466.72% 25.63B
-1.60%-2.60%-19.69%-14.84% 23.51B
+2.43%+5.86%+46.56%+0.42% 19.43B
-3.19%-0.29%+36.24%-27.32% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+10.46%+47.66% - 14.13B
-1.05%+1.75%+25.08%+196.28% 14.35B
Average -0.80%+1.09%+45.86%+199.30% 25.42B
Weighted average by Cap. -1.07%+0.30%+52.18%+162.12%

Financials

2026 *2027 *
Net sales 2.45M 3.28M 2.87M 2.65M 4.64M 313M 4.72M 31.66M 12.43M 154M 12.33M 12.06M 531M 42.03M 56.41M 49.34M 45.51M 79.76M 5.38B 81.1M 544M 214M 2.65B 212M 207M 9.11B
Net income -657M -882M -772M -712M -1.25B -84.14B -1.27B -8.5B -3.34B -41.45B -3.31B -3.24B -142B -680M -913M -799M -737M -1.29B -87.08B -1.31B -8.8B -3.46B -42.9B -3.43B -3.35B -147B
Net Debt -262M -351M -307M -283M -497M -33.5B -505M -3.39B -1.33B -16.5B -1.32B -1.29B -56.73B -11.05M -14.83M -12.97M -11.96M -20.97M -1.41B -21.32M -143M -56.13M -697M -55.67M -54.46M -2.39B
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
11/07/26 USD 15.25 -1.49% 2,638,459
09/07/26 USD 15.48 -1.34% 2,365,990
08/07/26 USD 15.69 -1.20% 2,775,792
07/07/26 USD 15.88 -0.31% 2,798,470
06/07/26 USD 15.93 +3.31% 3,922,125
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
11.55GBP
Average target price
21.41GBP
Spread / Average Target
+85.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SMMT Stock